| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BJH.12909 |
| P698 | PubMed publication ID | 24761838 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| Robert Schlossman | Q114300414 | ||
| Noopur Raje | Q114442101 | ||
| Teru Hideshima | Q114455520 | ||
| Diana D Cirstea | Q117224708 | ||
| Anuj K Mahindra | Q117224745 | ||
| Tyler A Scullen | Q117224746 | ||
| Parameswaran Hari | Q42118262 | ||
| Raffaella Marcheselli | Q57617104 | ||
| Paul G. Richardson | Q87712102 | ||
| Jacob P Laubach | Q87769541 | ||
| Irene Ghobrial | Q88032966 | ||
| Scott Rodig | Q88034786 | ||
| Nikhil V Munshi | Q89228014 | ||
| P2093 | author name string | Andrew J Yee | |
| Edie A Weller | |||
| Jill N Burke | |||
| P2860 | cites work | DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival | Q24311448 |
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy | Q24632296 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| Current development of mTOR inhibitors as anticancer agents | Q28255366 | ||
| mTOR and cancer therapy | Q28268516 | ||
| Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression | Q29617473 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. | Q31047994 | ||
| A phase 2 study of bortezomib in relapsed, refractory myeloma | Q33348702 | ||
| In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model | Q33362103 | ||
| Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma | Q33366976 | ||
| Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma | Q33383550 | ||
| Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study | Q33394281 | ||
| Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma | Q33401018 | ||
| Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study | Q33401457 | ||
| U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma | Q33408443 | ||
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study | Q33942495 | ||
| International uniform response criteria for multiple myeloma. | Q34549410 | ||
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling | Q35581650 | ||
| Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma | Q35915726 | ||
| Identification and validation of novel therapeutic targets for multiple myeloma | Q36254612 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor | Q37215171 | ||
| Novel therapeutic targets for multiple myeloma | Q37707383 | ||
| Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis | Q37806773 | ||
| Latest advances and current challenges in the treatment of multiple myeloma | Q37986287 | ||
| Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab | Q39627268 | ||
| Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. | Q39718152 | ||
| In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma | Q39768627 | ||
| Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis | Q40314252 | ||
| Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma | Q40524119 | ||
| Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. | Q40569009 | ||
| Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma | Q43726973 | ||
| Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma | Q43761443 | ||
| Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. | Q43901688 | ||
| Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial | Q44442859 | ||
| Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. | Q44732861 | ||
| Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. | Q46708758 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 401-409 | |
| P577 | publication date | 2014-04-25 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide | |
| P478 | volume | 166 |
| Q35236076 | Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. |
| Q38630472 | Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma |
| Q48110513 | Bone-Targeted Therapies in Cancer-Induced Bone Disease |
| Q93029473 | Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells |
| Q41694198 | Emerging drugs and combinations to treat multiple myeloma |
| Q38413040 | Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. |
| Q41346803 | Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing |
| Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
| Q92772115 | Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management |
| Q64230046 | NVP-BEZ235-induced autophagy as a potential therapeutic approach for multiple myeloma |
| Q48263465 | PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. |
| Q97681541 | Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma |
| Q38753307 | Signaling Pathways and Emerging Therapies in Multiple Myeloma |
| Q33429430 | TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia |
| Q51170783 | The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. |
| Q47107700 | VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. |
| Q92492516 | Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis |
| Q39113506 | m-TOR inhibitors and their potential role in haematological malignancies |
| Q42430902 | mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein |
| Q28087019 | mTOR: a potential therapeutic target in osteoarthritis? |
Search more.